Daina Graybosch
Stock Analyst at Leerink Partners
(1.28)
# 3,531
Out of 5,182 analysts
99
Total ratings
40%
Success rate
-6.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $115.07 | -0.06% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.25 | -11.11% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.40 | +42.86% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $28 | $8.31 | +236.94% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $3.56 | +96.63% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $22.12 | -45.75% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $110.23 | +7.96% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.96 | +303.23% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $86.74 | -48.12% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.31 | +663.36% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $24.95 | +52.30% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.35 | +83.91% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $102.06 | +119.48% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.83 | +960.07% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.83 | +1,948.19% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.92 | +208.22% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $115.07
Upside: -0.06%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.25
Upside: -11.11%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.40
Upside: +42.86%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $28
Current: $8.31
Upside: +236.94%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $3.56
Upside: +96.63%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $22.12
Upside: -45.75%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $110.23
Upside: +7.96%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.96
Upside: +303.23%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $86.74
Upside: -48.12%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.31
Upside: +663.36%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $24.95
Upside: +52.30%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.35
Upside: +83.91%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $102.06
Upside: +119.48%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.83
Upside: +960.07%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.83
Upside: +1,948.19%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.92
Upside: +208.22%